Therapeutic strategies for optimizing PDE-5 inhibitor therapy in patients with erectile dysfunction considered difficult or challenging to treat

I Sáenz de Tejada2026-03-222026-03-22200410.1038/sj.ijir.3901215https://doi.org/10.1038/sj.ijir.3901215https://andeanlibrary.org/handle/123456789/85789Citaciones: 38enErectile dysfunctionMedicinecGMP-specific phosphodiesterase type 5Nitric oxidePhosphodiesterasePharmacologyPhosphodiesterase inhibitorEndothelial dysfunctionDiabetes mellitusSildenafilTherapeutic strategies for optimizing PDE-5 inhibitor therapy in patients with erectile dysfunction considered difficult or challenging to treatreview